Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Significant Decline in Short Interest

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a large drop in short interest in August. As of August 31st, there was short interest totalling 31,000 shares, a drop of 57.5% from the August 15th total of 72,900 shares. Based on an average trading volume of 887,500 shares, the days-to-cover ratio is presently 0.0 days.

Several brokerages recently weighed in on BAYRY. Berenberg Bank dropped their price target on shares of Bayer Aktiengesellschaft from €74.00 ($87.06) to €60.00 ($70.59) and set a “buy” rating on the stock in a research report on Monday, August 9th. AlphaValue lowered shares of Bayer Aktiengesellschaft to a “buy” rating in a research note on Wednesday, August 4th. Credit Suisse Group reiterated a “neutral” rating on shares of Bayer Aktiengesellschaft in a research note on Friday, August 6th. DZ Bank reiterated a “buy” rating on shares of Bayer Aktiengesellschaft in a research note on Wednesday, May 26th. Finally, Kepler Capital Markets reiterated a “buy” rating on shares of Bayer Aktiengesellschaft in a research note on Friday, June 25th. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from, Bayer Aktiengesellschaft presently has a consensus rating of “Buy” and an average target price of $39.00.

Shares of BAYRY stock opened at $13.48 on Friday. The company has a 50 day moving average of $14.29 and a 200-day moving average of $15.43. The company has a quick ratio of 0.80, a current ratio of 1.16 and a debt-to-equity ratio of 1.20. Bayer Aktiengesellschaft has a 12-month low of $11.65 and a 12-month high of $17.34. The firm has a market cap of $52.97 billion, a P/E ratio of -16.85, a PEG ratio of 3.32 and a beta of 1.27.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings results on Thursday, August 5th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.46 by $0.02. Bayer Aktiengesellschaft had a negative net margin of 6.30% and a positive return on equity of 19.76%. The company had revenue of $13.08 billion during the quarter, compared to analyst estimates of $11.83 billion. As a group, equities analysts expect that Bayer Aktiengesellschaft will post 1.79 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents.

See Also: When is a capital gain realized?

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with's FREE daily email newsletter.